Expert Point of View: Nabil F. Saba, MD, FACP
“It’s becoming more and more clear that increasing the cytotoxic effect of treatment and expecting to get a better outcome is an approach of the past,” said Nabil F. Saba, MD, FACP, the Lynne and Howard Halpern Chair in Head and Neck Cancer Research, Professor and Vice Chair ofHematology and Medical Oncology, and Co-Director of the Head and Neck Cancer Multidisciplinary Program at Winship Cancer Insitute, Emory University. “We’re currently in the era of de-escalation in HPV-positive disease.”
According to Dr. Saba, the ECOG 3311 trial showed that low-risk human papillomavirus (HPV)-related cancer can be adequately treated with transoral robotic surgery followed by radiation therapy in a selected group, but several questions remain: What is the best approach for patients with high-risk pathologic features after surgical resection? The trial shows us that treating these patients with cisplatin and radiation is adequate, he added, but should it remain the standard of care, or is there an alternative approach for these patients?
“ECOG 3311 basically proves this approach is valid and useful in low-risk HPV-related disease,” he said. “However, the question of whether it is equivalent to definitive therapy—in other words, nonsurgical therapy—remains a question that deserves to be answered in a subsequent phase III trial.”
Dr. Saba also pointed out some challenges to the trial. “You’re randomly assigning patients to two completely different modalities, and patients and physicians may have their own convictions as to how patients should be treated,” he noted. “Until this trial is done, I don’t think we’re going to be able to set the definitive standard of care for these patients. However, my belief is that many centers will use ECOG 3311 as proof that it is a useful modality, and this will continue to be utilized for patients with low-risk HPV-related disease.”
Finally, the question of de-escalation remains an interesting one, according to Dr. Saba. “The HN005 trial will hopefully answer the question of whether it is possible to de-escalate in a nonsurgical fashion,” he said. “Once this trial matures and is able to report, I’m sure it will add to the ECOG 3311 discussion; however, I suspect these HPV- specific trials will take a while to mature.”
DISCLOSURE: Dr. Saba has served as an advisor and received compensation from Eisai, Astra Zeneca, Merck, WebMD, OncLive, Mirati, Reach MD, Vaccinex, Kura, Biontech, GSK, Aduro, and Pfizer; and has received research funding from BMS and Exelixis.